Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141788 | 1.00 | CA1 (0.36) | CA1CA2CA4CA7F2 | |
| SCHEMBL19650262 | 1.00 | CA1 (0.36) | CA1CA2CA4CA7F2 | |
| Hydrochloric Acid SCHEMBL3370361 | 0.99 | CA1 (0.36) | CA1CA2CA4CA7F2 | |
| SCHEMBL30496307 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| SCHEMBL30607155 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| SCHEMBL12834785 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| SCHEMBL12860070 | 0.89 | CYP2D6 (0.45) | CYP2D6CHEK2PIM1 | |
| Hydrochloric Acid SCHEMBL2744323 | 0.85 | GRIK1 (0.35) | CYP2D6 | |
| SCHEMBL6769372 | 0.79 | P2RX3 (0.46) | PIM1 | |
| SCHEMBL6769375 | 0.79 | P2RX3 (0.46) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9452154-B2 | Methods for treating HCV | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452154-B2 | Methods for treating HCV | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9393256-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393256-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150141353-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141353-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013040492-A2 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243726-A1 | METHODS FOR TREATING HCV | HAVCR2, DHFR, HCCS | CA1 3664/4885CA2 3202/4885CA4 2686/4885 |
| US-20160354425-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CA1 3673/4885CA2 2505/4885CA4 2410/4885 |
| US-20130273005-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CA1 3673/4885CA2 2505/4885CA4 2410/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CA1 3673/4885CA2 2505/4885CA4 2410/4885 |
| US-20150141353-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CA1 3673/4885CA2 2505/4885CA4 2410/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CA1 3673/4885CA2 2505/4885CA4 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.